Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

"Overall, metabolic responses to glucagon stimulation in individuals with type 1 diabetes are comparable to those in healthy ...

Novo Nordisk’s amycretin shows 22% weight loss over 36 weeks, potentially surpassing Eli Lilly’s Zepbound. Further trials are ...

The latest buzz around the popular weight loss drugs Ozempic, Mounjaro and Wegovy is to reduce the doseage to avoid the negative effects of normal doses. But does it have dangers too? Jessica Salter r ...

Novo Nordisk has reported topline outcomes from a Phase Ib/IIa trial of amycretin designed for treating obese or overweight ...

The liver and pancreas are the main actors in glucose metabolism, but not the only ones. Muscles, adipose tissue and the brain play different roles. However, the prize for the best new actor in ...

On the other hand, when your blood sugar levels drop too low, your pancreas releases the hormone glucagon, which raises your ...

Results from Novo Nordisk's STEP UP trial show that a high-dose formulation of Wegovy can significantly increase the weight ...

Semaglutide combined with automated insulin delivery enhances glucose control in type 1 diabetes, lowering insulin ...

The two organizations will produce educational materials about the medicine and its importance for people living with type 1 ...

Tirzepatide was a highly effective treatment for improving metabolic parameters, including insulin resistance, fasting insulin, and fasting glucagon among individuals with T2D and obesity. Higher ...

A systematic review of 26 randomized controlled trials (RCTs) finds that among glucagon-like peptide 1 ... patients had at least a month of a fixed dose. Not surprisingly, the review found ...